Yue XF et al. |
Cytotoxic activity of trewiasine in 4 human cancer cell lines and 5 murine tumors. |
1992 |
Zhongguo Yao Li Xue Bao |
pmid:1442109
|
Fan YJ et al. |
[Effect of maytansine on the cell cycle of Ehrlich ascites carcinoma cells in mice]. |
1985 |
Zhongguo Yao Li Xue Bao |
pmid:3158164
|
Yang JL et al. |
[Antitumor activity of trewiasine in vitro and in vivo]. |
1988 |
Zhongguo Yao Li Xue Bao |
pmid:3256213
|
Wang XF et al. |
[Studies on the antitumor constituents of Maytenus confertiflora Luo et Chen (Celastraceae). II. Isolation and characterization of maytansine and maytanprine from the stems]. |
1981 |
Yao Xue Xue Bao |
pmid:7324964
|
Fan YJ et al. |
[Use of 1,2:5,6-dianhydrogalactitol in combination with maytansine in experimental tumor therapy]. |
1983 |
Yao Xue Xue Bao |
pmid:6677049
|
Vilela MD et al. |
Progressively Enlarging Cerebellar Hematoma Concurrent with T-DM1 Treatment. |
2018 |
World Neurosurg |
pmid:29274446
|
Niell HB et al. |
Effect of concentration and time of drug exposure on clonal growth of murine bladder cancer. |
1985 |
Urology |
pmid:2579500
|
Milowsky MI et al. |
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. |
2016 |
Urol. Oncol. |
pmid:27765518
|
Roviello G et al. |
Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. |
2016 |
Tumour Biol. |
pmid:26566626
|
Faião-Flores F et al. |
Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells. |
2013 |
Tumour Biol. |
pmid:23341182
|
De Angelis C et al. |
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. |
2013 May-Jun |
Tumori |
pmid:24158083
|
Poon KA et al. |
Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. |
2013 |
Toxicol. Appl. Pharmacol. |
pmid:24035823
|
Wehrli W |
Ansamycins. Chemistry, biosynthesis and biological activity. |
1977 |
Top Curr Chem |
pmid:74108
|
Hull RN et al. |
Studies on tissue culture produced plasminogen activator. I. Preliminary observations and the enhancing effect of colchicine and other antimitotic agents. |
1977 |
Thromb. Res. |
pmid:18812
|
Liang Y et al. |
A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid. |
2017 |
Theranostics |
pmid:28900511
|
Vankemmelbeke M and Durrant L |
Third-generation antibody drug conjugates for cancer therapy--a balancing act. |
2016 |
Ther Deliv |
pmid:26893243
|
Sieber SM et al. |
Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice. |
1978 |
Teratology |
pmid:694777
|
Kosmin M et al. |
Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. |
2017 |
Target Oncol |
pmid:28110417
|
Diéras V and Bachelot T |
The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. |
2014 |
Target Oncol |
pmid:23852665
|
Iwasaki S |
[Inhibitors of tubulin assembly: specially on rhizoxin-maytansine site ligands]. |
1993 |
Tanpakushitsu Kakusan Koso |
pmid:8210422
|